- Press Releases
- Notices
Press Releases To List
-
- Mar.26.2026R & D
- Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
-
- Mar.23.2026R & D
- Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
-
- Mar.11.2026R & D
- Vertex Announces Positive Week 36 Interim Analysis Results from the Global RAINIER Phase 3 Trial of Povetacicept
-
- Mar.09.2026Sustainability
- Ono Pharma Selected as "2026 Health & Productivity Stock"
-
- Mar.05.2026Management / Finance
- Notice Concerning Disposal of Treasury Shares by Third-Party Allotment
Notices To List
-
- Mar.26.2026Corporate
- Notice about Posting of the Sustainability Day Script
-
- Feb.04.2026Corporate
- Notice about Posting of the Financial Result Meeting for FY2025 Q3 - Script
-
- Jan.15.2026Corporate
- The 44th Annual J.P. Morgan Healthcare Conference Presentation Materials Posted
-
- Nov.04.2025Corporate
- Notice about Posting of the Financial Result Meeting for FY2025 Q2 - Script
-
- Sep.29.2025Corporate
- Corporate Report 2025 has been released.
About
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.
